EPS

Facing a Nasdaq delisting threat, China-based WF International has 180 days to revive its stock after a dramatic collapse since its April IPO.

Investors await Polaris's Q4 results on Jan. 27, seeking clarity on market share gains, tariff impacts, and the future of its Indian Motorcycle brand.

As Axos sets to reveal its Q2 results, investors weigh strong growth forecasts against mounting concerns over margin pressure and a shifting economy.

Veracyte prepares for the J.P. Morgan conference, where it will showcase its AI and genomic strategy amid strong financials and a competitive market.

After 16 years, Chief Legal Officer Anthony Green announces his retirement, leaving a void at the top and questions about Annaly's future governance.

As Northern Trust prepares its Q4 2025 earnings call, investors seek clues on its resilience amid shifting economic tides and strategic digital pivots.

After a turbulent year, the sleep apnea device maker aims to prove its rocky product launch is behind it and convince investors of a strong 2026.

EUDA Health's new Helixé 2.0 supplement boasts enhanced potency, nano-delivery tech, and Halal certification to capture the booming global wellness market.

American Express has locked in its 2026 earnings call schedule. Here’s what investors and analysts will be watching for amid shifting economic signals.

A major acquisition turned sour, a 25% stock crash, and now a class action lawsuit. Inside Perrigo's costly infant formula venture and what it means.

Precious metals soar in 2025, with silver's 128% surge fueled by geopolitical turmoil, economic fears, and a booming demand from green tech and AI.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

The insurer's routine preferred stock dividend declaration masks a deeper story of record profits, strategic execution, and strong analyst confidence.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

IGM Financial has nearly doubled its share buyback authorization, a bold move signaling deep confidence. What does this mean for investors and the industry?

A new study reveals Gen X faces a shocking $400K retirement shortfall, caught between fading pensions and an imperfect 401(k) system. Are they prepared?

The Nasdaq-listed restaurant operator confirms its board and auditor, signaling stability as it navigates a volatile stock performance and dynamic F&B sector.

Pfizer projects lower 2026 earnings as COVID sales wane and patents expire, shifting focus to a multi-billion dollar R&D push for future growth.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

The junior explorer is expanding its footprint in a hot gold district. We analyze the financial mechanics, shareholder impact, and leadership incentives.